For: | Broquetas T, Garcia-Retortillo M, Micó M, Canillas L, Puigvehí M, Cañete N, Coll S, Viu A, Hernandez JJ, Bessa X, Carrión JA. Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients. World J Hepatol 2020; 12(11): 1076-1088 [PMID: 33312431 DOI: 10.4254/wjh.v12.i11.1076] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v12/i11/1076.htm |
Number | Citing Articles |
1 |
Teresa Broquetas, José A Carrión. Past, present, and future of long-term treatment for hepatitis B virus. World Journal of Gastroenterology 2023; 29(25): 3964-3983 doi: 10.3748/wjg.v29.i25.3964
Abstract(450) |
Core Tip(465) |
Full Article(HTML)(3555)
|
Full Article with Cover (PDF)-2143K(110)
|
Full Article (Word)-469K(26)
|
Audio-340K(0)
|
Peer-Review Report-317K(35)
|
Answering Reviewers-65K(33)
|
Full Article (PDF)-890K(308)
|
Full Article (XML)-395K(33)
|
Times Cited (4)
|
Total Visits (6965)
|
Open
|
2 |
Teresa Broquetas, Juan-Jose Hernandez, Montserrat Garcia-Retortillo, Lidia Canillas, Marc Puigvehí, Nuria Cañete, Susanna Coll, Ana Viu, Esther Garrido, Miquel Mico, Xavier Bessa, José A. Carrión. On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty. Digestive and Liver Disease 2022; 54(8): 1044 doi: 10.1016/j.dld.2021.12.017
|
3 |
Rafaela Pires da Silva, João Ismael Budelon Gonçalves, Rafael Fernandes Zanin, Felipe Barreto Schuch, Ana Paula Duarte de Souza. Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.657363
|
4 |
Margarita Papatheodoridi, George Papatheodoridis. Hepatitis B Virus and Liver Disease. 2021; : 267 doi: 10.1007/978-981-16-3615-8_12
|
5 |
Yan-jie Lin, Fang-fang Sun, Zhan Zeng, Xiao-yue Bi, Liu Yang, Ming-hui Li, Yao Xie. Combination and Intermittent Therapy Based on Pegylated Interferon Alfa-2a for Chronic Hepatitis B with Nucleoside (Nucleotide) Analog-Experienced Resulting in Hepatitis B Surface Antigen Clearance: A Case Report. Viral Immunology 2022; 35(1): 71 doi: 10.1089/vim.2021.0112
|
6 |
Mariem Znaidia, Caroline Demeret, Sylvie van der Werf, Anastassia V. Komarova. Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options. Viruses 2022; 14(6): 1247 doi: 10.3390/v14061247
|
7 |
Hui Li, Caie Wang, Lu Chai, Xingshun Qi. Combination treatment of pegylated interferon and tenofovir versus tenofovir for people with chronic hepatitis B. Cochrane Database of Systematic Reviews 2023; 2023(8) doi: 10.1002/14651858.CD015730
|
8 |
Yujing Li, Fada Wang, Jing Zhou, Lanqing Li, Chengrun Song, Enqiang Chen. Optimal Treatment Based on Interferon No Longer Makes Clinical Cure of Chronic Hepatitis B Far Away: An Evidence‐Based Review on Emerging Clinical Data. Clinical Pharmacology & Therapeutics 2024; 116(2): 295 doi: 10.1002/cpt.3287
|
9 |
Teresa Broquetas, José A Carrión. Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus. Hepatic Medicine: Evidence and Research 2022; : 87 doi: 10.2147/HMER.S291976
|